Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews · Airways

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 20%GRADE not reported 0 · 0%Very low 4 · 80%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Macrolide+tetracycline vs macrolides

Quality of life, measured by CRQ (dyspnoea, fatigue, emotional function, and mastery subscales) · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 187 participants
Very low

Macrolide+tetracycline vs macrolides

All‐cause serious adverse events 60 weeks (end of study) · patients with chronic obstructive pulmonary disease

It is very uncertain whether macrolide+tetracycline changes all‐cause serious adverse events 60 weeks (end of study) compared with macrolide (very low certainty).

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
OR 1 [0.52, 1.93]
1 study · 198 participants
Very low

Macrolide+tetracycline vs macrolides

Change in baseline trough FEV1 · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 182 participants
Very low

Macrolide+tetracycline vs macrolides

All‐cause mortality 60 weeks (end of study) · patients with chronic obstructive pulmonary disease

It is very uncertain whether macrolide+tetracycline changes all‐cause mortality 60 weeks (end of study) compared with macrolide (very low certainty).

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
OR 1.63 [0.38, 7.02]
1 study · 198 participants
Very low

Macrolide+tetracycline vs macrolides

Number of people experiencing one or more exacerbations, Drug resistance/microbial sensitivity (as reported by trialists), including emergence of atypical bacteria, Number of participants colonised with Pseudomonas aeruginosa · patients with chronic obstructive pulmonary disease

The review found no eligible studies for this question.

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found